You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Preliminary NICE ‘no’ for Merck’s Bavencio

The National Institute for Health and Care Excellence (NICE) has issued a preliminary rejection of NHS funds for use of Merck Serono’s Bavencio (avelumab) as maintenance treatment of locally advanced or metastatic urothelial cancer.